Browse ADMET evidence entries by endpoint, reported value, assay context, interpretation role, and reference link. These counts indicate evidence availability, not safety, efficacy, or confidence by themselves.
Endpoints
17
·
Context signals
3,678
Measurements
39,523
Interpretation: Record counts indicate evidence availability, not safety, efficacy, or confidence by themselves. Use the ADMET-domain index and role filters to narrow the evidence-entry table before comparing values.
Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.
Plecanatide is minimally absorbed with negligible systemic availability following oral administration. Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (t½) cannot be calculated.
